報價延遲最少15分鐘:2025/04/12 04:14 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.7312 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-15.65/--
|
|
企業價值
13.42M
|
| 資產負債 |
|
每股賬面淨值
0.69
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/04/12 04:14 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. |